NCT04432259

Brief Summary

This study aims to determine if oral dexamethasone provides clinically significant improvement in postoperative outcomes, specifically nausea and pain scores.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
109

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Aug 2020

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 12, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 16, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

August 1, 2020

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2021

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
3.8 years until next milestone

Results Posted

Study results publicly available

September 25, 2026

Completed
Last Updated

September 25, 2026

Status Verified

September 1, 2026

Enrollment Period

1.1 years

First QC Date

June 12, 2020

Results QC Date

February 16, 2024

Last Update Submit

September 1, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Postoperative Pain

    Postoperative pain will be collected via visual analog scale (VAS) scores, from 0 to 10, 0 being no pain, 10 being severe pain. Average VAS score will be reported for each group.

    7 days following surgery

Study Arms (2)

Arm B: Oral Dexamethasone

EXPERIMENTAL

Participants will be randomly assigned to receive 4 mg Oral Dexamethasone taken twice daily for 4 days

Drug: Dexamethasone

Arm A: Placebo

PLACEBO COMPARATOR

Participants will be randomly assigned to receive 4 mg placebo taken twice daily for 4 days

Drug: Placebo

Interventions

4 mg bid for 4 days

Arm B: Oral Dexamethasone

oral placebo

Arm A: Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • adult patients age 18 and older who will be undergoing joint replacement

You may not qualify if:

  • Patients with uncontrolled diabetes ( HbA1C, \>7.5%), impaired hepatic function (Child class, \>B), impaired renal failure (Glomerular filtration rate \<60 mL/min/1.73 m2), chronic narcotic use, alcohol and/or opioid dependence, patients with a known adverse reaction to corticosteroids, and patients unable to give informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Henry Ford Medical Center - Cottage

Grosse Pointe Farms, Michigan, 48236, United States

Location

MeSH Terms

Conditions

Postoperative Nausea and VomitingPain, Postoperative

Interventions

Dexamethasone

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsNauseaSigns and Symptoms, DigestiveSigns and SymptomsVomitingPainNeurologic Manifestations

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Results Point of Contact

Title
Dr. Jason Davis
Organization
Henry Ford Health

Study Officials

  • Jason Davis, M.D.

    Henry Ford Health System

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Participants will be randomly assigned to one of two groups, treatment or no treatment. Randomizations will be balanced at random accrual points.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 12, 2020

First Posted

June 16, 2020

Study Start

August 1, 2020

Primary Completion

September 1, 2021

Study Completion

December 1, 2022

Last Updated

September 25, 2026

Results First Posted

September 25, 2026

Record last verified: 2026-09

Locations